Literature DB >> 12381912

Unexpected renal actions of erythropoietin.

Christof Westenfelder1.   

Abstract

Erythropoietin (EPO) in the renal cortex is synthesized by fibroblast-like cells that are in direct contact with capillaries and adjacent tubular cells. Prompted by this anatomical relationship, we asked whether renal cells express EPO receptors (EPORs) through which EPO could act as a renotropic cytokine. We found that all regions of human, rat and mouse kidney, mesangial and proximal and distal tubular cells express authentic EPORs. Similar EPOR expression was detected in kidney cancer cells, and in cyst epithelia from polycystic kidneys. In vitro, EPO stimulated mitogenesis in all normal and malignant cells, and cell survival and motogenesis in injured tubular cells. Since the normal kidney is essentially unresponsive to EPO, we hypothesized that EPO's cytokine effects in the kidney are revealed when tubular cells are induced to proliferate by a prior insult, as occurs in acute renal failure. Accordingly, we found that EPO treatment of rats with 'ischemic' acute renal failure afforded renoprotection and accelerated functional recovery. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381912     DOI: 10.1159/000065304

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  10 in total

1.  Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.

Authors:  Florian E Tögel; Jon D Ahlstrom; Ying Yang; Zhuma Hu; Ping Zhang; Christof Westenfelder
Journal:  J Am Soc Nephrol       Date:  2016-03-16       Impact factor: 10.121

Review 2.  The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.

Authors:  Volker H Haase
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

3.  Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice.

Authors:  Nicoletta Eliopoulos; Jing Zhao; Kathy Forner; Elena Birman; Yoon Kow Young; Manaf Bouchentouf
Journal:  Mol Ther       Date:  2011-08-16       Impact factor: 11.454

4.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 5.  Recombinant erythropoietin in clinical practice.

Authors:  T Ng; G Marx; T Littlewood; I Macdougall
Journal:  Postgrad Med J       Date:  2003-07       Impact factor: 2.401

6.  Erythropoietin update 2011.

Authors:  Mariusz Kowalczyk; Maciej Banach; Dimitri P Mikhailidis; Jacek Rysz
Journal:  Med Sci Monit       Date:  2011-11

7.  Restoration of Haemoglobin Level Using Hydrodynamic Gene Therapy with Erythropoietin Does Not Alleviate the Disease Progression in an Anaemic Mouse Model for TGFβ1-Induced Chronic Kidney Disease.

Authors:  Lea Pedersen; Lise Wogensen; Niels Marcussen; Claudia R Cecchi; Trine Dalsgaard; Frederik Dagnæs-Hansen
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

8.  The expression of EPOR in renal cortex during postnatal development.

Authors:  Lu Xiao; Zhanyong Li; Pengjuan Xu; Zhigui Li; Jing Xu; Zhuo Yang
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

9.  Improving outcomes of acute kidney injury using mouse renal progenitor cells alone or in combination with erythropoietin or suramin.

Authors:  Xiao Han; Li Zhao; Guodong Lu; Junke Ge; Yalin Zhao; Shulu Zu; Mingzhen Yuan; Yuqiang Liu; Feng Kong; Zhiying Xiao; Shengtian Zhao
Journal:  Stem Cell Res Ther       Date:  2013-06-18       Impact factor: 6.832

Review 10.  The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection.

Authors:  Piotr Bartnicki; Mariusz Kowalczyk; Jacek Rysz
Journal:  Med Sci Monit       Date:  2013-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.